Table 2: Independent Predictors of Post-discharge Mortality in Randomised Controlled Trials.
RCT | Year of publication | Sample size | Prediction period | Independent predictor results from multivariate analysis |
---|---|---|---|---|
OPTIME-CHF[17]17 | 2004 | 949 | 60-day mortality | Age; NYHA functional class; SBP; BUN; sodium |
ESCAPE[18] | 2010 | 423 | 6-month mortality | BNP; cardiopulmonary resuscitation or mechanical ventilation during hospitalisation; blood urea nitrogen; serum sodium, age >70 years; daily loop diuretic, furosemide equivalents >240 mg; lack of betablocker; 6-min walk test |
PROTECT[19] | 2016 | 1990 | 90-day mortality | Age; COPD; SBP; WBC count; serum sodium; bicarbonate; BUN; uric acid |
CHARM[20] | 2007 | 7572 | 2-year mortality | Age; LVEF; diabetes-insulin treated; low BMI; male; NYHA Class IV; current smoker; cardiomegaly; prior HF hospitalisation within 6 months |
ASCEND HF[21] | 2015 | 7141 | 30-day and 180-day mortality | Age; BUN; baseline sodium, SBP>140 mmHg; baseline dyspnoea |
ASCEND-HF = Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; BMI = body mass index; BNP = brain natriuretic peptide; BUN = blood urea nitrogen; CHARM = Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity; COPD = chronic obstructive pulmonary disease; ESCAPE = Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF = heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OPTIME-CHF = Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure; PROTECT = Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal function; RCT = randomised clincal trial; SBP = systolic blood pressure; WBC = white blood count.